Main menu button

Equity Research Svenska Aerogel, Q2 2023: Lower than expected revenues but positive development with key customers

30 Aug 2023

Today, Svenska Aerogel published its interim report for the second quarter of 2023. Below is a summary of our first impressions of the report’s outcome and the income statement’s deviations from our forecasts.

  • During the second quarter of 2023, Svenska Aerogel experienced a slowdown in contrast to the strong sales growth observed from Q3 2022 to Q1 2023. However, the company sees a positive development with several key customers, which will probably be reflected in the figures at a later date Furthermore, on the evening of August 29, 2023, the company made the decision to issue a convertible loan to its primary stakeholder, Gästrike Nord Invest AB. The primary intent behind this move is primarily to refinance a convertible loan that was initially secured in February 2023. This earlier loan is set to mature on August 31, 2023.
  • Net sales in the second quarter of 2023 for Svenska Aerogel amounted to SEK 0,3 million, which corresponds to a negative growth of approximately 13 percent compared to Q2 2022. Our forecast of SEK 2.8 million in total revenue was thus significantly higher than the outcome.
  • EBITDA amounted to minus SEK 9.7 million. Our EBITDA forecast was minus SEK 9.1 million. The difference is mainly attributable to higher than expected S&G costs and administration costs.
  • The net result for Q2 2023 was minus SEK 12.2 million, lower than our forecast of minus SEK 9.1 million.

We intend to provide an updated research report on Svenska Aerogel report shortly.

Read our initiation report for Svenska Aerogel here.


Carlsquare AB,, hereinafter referred to as Carlsquare, is engaged in corporate finance and equity research, publishing information on companies and including analyses. The information has been compiled from sources that Carlsquare deems reliable. However, Carlsquare cannot guarantee the accuracy of the information. Nothing written in the analysis should be considered a recommendation or solicitation to invest in any financial instrument, option, or the like. Opinions and conclusions expressed in the analysis are intended solely for the recipient.

The content may not be copied, reproduced, or distributed to any other person without the written consent of Carlsquare. Carlsquare shall not be liable for either direct or indirect damages caused by decisions made on the basis of information contained in this analysis. Investments in financial instruments offer the potential for appreciation and gains. All such investments are also subject to risks. The risks vary between different types of financial instruments and combinations thereof. Past performance should not be taken as an indication of future returns.

The analysis is not directed at U.S. Persons (as that term is defined in Regulation S under the United States Securities Act and interpreted in the United States Investment Companies Act of 1940), nor may it be disseminated to such persons. The analysis is not directed at natural or legal persons where the distribution of the analysis to such persons would involve or entail a risk of violation of Swedish or foreign laws or regulations.

The analysis is a so-called Assignment Analysis for which the analyzed company has signed an agreement with Carlsquare for analysis coverage. The analyses are published on an ongoing basis during the contract period and for the usually fixed fee.

Carlsquare may or may not have a financial interest with respect to the subject matter of this analysis. Carlsquare values the assurance of objectivity and independence and has established procedures for managing conflicts of interest for this purpose.

The analysts Christopher Solbakke and Bertil Nilsson do not own and may not own shares in the analyzed company

Equity Research Svenska Aerogel, Q2 2023: Lower than expected revenues but positive development with key customers